Sagent Pharmaceuticals Announces Launch of Irinotecan Hydrochloride Injection in Single Dose Vials
SCHAUMBURG, Ill., May 17, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Irinotecan Injection, the generic form of the chemotherapy drug Camptosar®, in two latex free, preservative free single dose vials. According to IMS data for the twelve-months ended March 2012, the U.S. market for Irinotecan approximated $28 million. As with all products in Sagent's portfolio, Irinotecan features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.
About Irinotecan Injection
Irinotecan hydrochloride injection is an antineoplastic agent of the topoisomerase I inhibitor class. It is indicated in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
The package insert, which is available at www.sagentpharma.com, contains detailed information about the indications, complete side effect profile, boxed warnings and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive pharmaceutical product portfolio that fulfills the evolving needs of patients.
CONTACT: INVESTOR CONTACT:
Jonathon Singer, Sagent
Source: Sagent Pharmaceuticals, Inc.
News Provided by Acquire Media
Close window | Back to top